The American Journal of Managed Care1h
Fixed-Duration 1L CLL Treatment Reduces Long-Term Costs in the Real World
The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...
The American Journal of Managed Care16h
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...
The American Journal of Managed Care21h
Exploring Metabolic Links to Cognitive Impairment in MS
The complex relationship between possibly impaired cognitive function in patients with multiple sclerosis (MS) and fasting ...
The American Journal of Managed Care22h
5 Things About State Votes to Protect Abortion Rights
A total of 7 states passed ballot measures during the 2024 presidential election to enshrine abortion access into their state ...
The American Journal of Managed Care19h
Sunvozertinib NDA Submitted to FDA for NSCLC
A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...
The American Journal of Managed Care23h
Shared Decision Making is Essential Prior to SMA-Enhancing Treatments
Perspectives of patients with spinal muscular atrophy (SMA) and their caregivers should be weighed before making decisions around SMA-enhancing treatments.